The estimated Net Worth of Chad A. Mirkin is at least $17.7 Millón dollars as of 12 June 2020. Chad Mirkin owns over 10,195 units of Exicure Inc stock worth over $17,449,325 and over the last 6 years he sold XCUR stock worth over $28,852. In addition, he makes $206,948 as Director at Exicure Inc.
Sign up
Chad Mirkin XCUR stock SEC Form 4 insiders trading
Chad has made over 7 trades of the Exicure Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 10,195 units of XCUR stock worth $28,852 on 12 June 2020.
The largest trade he's ever made was exercising 49,649 units of Exicure Inc stock on 20 May 2020 worth over $32,272. On average, Chad trades about 11,372 units every 50 days since 2019. As of 12 June 2020 he still owns at least 11,257,629 units of Exicure Inc stock.
You can see the complete history of Chad Mirkin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Chad Mirkin biography
Dr. Chad A. Mirkin Ph.D. serves as Director of the Company. He has served as a member of our Board of Directors since June 2011. He has also provided consulting services to us since October 2011. Dr. Mirkin is the Director of the International Institute for Nanotechnology at Northwestern University, as well as the George B. Rathmann Professor of Chemistry, Professor of Chemical and Biological Engineering, Professor of Biomedical Engineering, Professor of Materials Science and Engineering, and Professor of Medicine. Dr. Mirkin is a fellow of the American Association for the Advancement of Science and the National Academy of Engineering. Dr. Mirkin served on the President’s Council of Advisors on Science and Technology during the Obama administration from April 2009 to January 2017. Dr. Mirkin is one of the founders of, and has served as president and as a member of the board of managers of, AuraSense, LLC, our largest stockholder, since December 2009. Dr. Mirkin served as a director of Nanosphere, Inc., from 2000 until May 2013, and NanoInk, Inc., from 2002 to 2010. Dr. Mirkin holds a B.S. from Dickinson College and a Ph.D. in chemistry from Pennsylvania State University. Our Board believes that Dr. Mirkin’s significant scientific knowledge, expertise in the application of nanotechnology to the development of nucleic acid products and experience in leadership positions qualify him to serve on the Board.
What is the salary of Chad Mirkin?
As the Director of Exicure Inc, the total compensation of Chad Mirkin at Exicure Inc is $206,948. There are 3 executives at Exicure Inc getting paid more, with David Giljohann having the highest compensation of $785,462.
How old is Chad Mirkin?
Chad Mirkin is 56, he's been the Director of Exicure Inc since 2020. There are 3 older and 8 younger executives at Exicure Inc. The oldest executive at Exicure Inc is David Walt, 67, who is the Independent Director.
What's Chad Mirkin's mailing address?
Chad's mailing address filed with the SEC is C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE, IL, 60077.
Insiders trading at Exicure Inc
Over the last 6 years, insiders at Exicure Inc have traded over $4,850,172 worth of Exicure Inc stock and bought 7,217,940 units worth $10,705,021 . The most active insiders traders include Timothy P Walbert, Co., Ltd. Dgp y Usa, Inc. Cbi. On average, Exicure Inc executives and independent directors trade stock every 90 days with the average trade being worth of $928,360. The most recent stock trade was executed by Co., Ltd. Dgp on 29 February 2024, trading 3,400,000 units of XCUR stock currently worth $4,488,000.
What does Exicure Inc do?
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
What does Exicure Inc's logo look like?
Complete history of Chad Mirkin stock trades at Exicure Inc
Exicure Inc executives and stock owners
Exicure Inc executives and other stock owners filed with the SEC include:
-
David Giljohann,
Chief Executive Officer, Interim Principal Financial Officer, Corporate Secretary, Director -
Matthias Schroff,
Chief Operating Officer -
Dr. Douglas E. Feltner,
Chief Medical Officer -
Chad Mirkin,
Director -
Bali Muralidhar,
Independent Director -
Bosun Hau,
Independent Director -
Jay Venkatesan,
Independent Director -
Helen Kim,
Independent Director -
Timothy Walbert,
Independent Chairman of the Board -
David Walt,
Independent Director -
Jeffrey Cleland,
Independent Director -
Karen Sharma,
Investor Relations -
Bart Anderson,
Sr. Director of R&D -
Dr. Emil M. deGoma M.D.,
VP of Clinical Devel. -
Weston Daniel,
VP of Translational Research -
Sarah Longoria,
VP of HR -
Christoph Jaeker,
VP of Corp. Devel. & Strategy -
Elias D. Papadimas,
Chief Accounting Officer -
Brian C. Bock,
Chief Financial Officer -
Elizabeth A. Garofalo,
Director -
Andy Sassine,
Director -
Llc Aurasense,
10% owner -
Douglas E. Feltner,
Chief Medical Officer -
James R Sulat,
Director -
Colby Shad Thaxton,
Director -
David S Snyder,
Chief Financial Officer -
Frontier, Llcgates William ...,
-
Brian Bock,
Chief Financial Officer -
Co., Ltd. Dgp,
-
Elias D. Papadimas,
Chief Financial Officer -
Sarah Longoria,
Chief HR & Compliance Officer -
Usa, Inc. Cbi,
-
Jiyoung Hwang,
Director -
Josh Miller,
Chief Accounting Officer